353.
Daniele Mipatrini, Chiara Montaldo, etc.,
‘Disease X’—time to act now and prepare for the next pandemic threat, 2022.10.17,
https://academic.oup.com/eurpub/article/32/6/841/6762033 .
It is now the time to leverage the recent experience of the COVID-19 pandemic, to plan the preparedness for the future, to update the global governance and legislation and to produce international guidelines for preparedness to respond to the next Disease X.
352.
Kyla Tozer, Calvin P Sjaarda, etc.,
Comparison of SARS-CoV-2 Viral Loads in the Nasal Mucosa of Patients Infected With BA.1, BA.2, or BA.5 Omicron Lineages, 2022.10.22,
https://academic.oup.com/ofid/article/9/12/ofac564/6769953 .
Lower viral loads were observed in the upper respiratory tract of patients infected with BA.1, whereas patients infected with BA.2 and BA.5 had comparable viral loads to those seen with Alpha or Delta. This suggests that viral loads are likely not responsible for the increased transmission of the Omicron lineages.
351.
Simiso Sokhela, Bronwyn Bosch, etc.,
Comparing Prospective Incident Severe Acute Respiratory Syndrome Coronavirus 2 Infection Rates During Successive Waves of Delta and Omicron in Johannesburg, South Africa, 2022.12.16,
https://academic.oup.com/ofid/article/9/12/ofac587/6916963 .
In high-risk individuals in Johannesburg, during the Delta coronavirus disease 2019 wave, 22% (125/561) were positive, with 33% symptomatic (2 hospitalizations; 1 death). During Omicron, 56% (232/411) were infected, with 24% symptomatic (no hospitalizations or deaths). The remarkable speed of infection of Omicron over Delta poses challenges to conventional severe acute respiratory syndrome coronavirus 2 control measures.
350.
Haruka Maeda, Nobuo Saito, etc.,
Effectiveness of Messenger RNA Coronavirus Disease 2019 Vaccines Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Delta Variant Epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS), 2022.04.19,
https://academic.oup.com/cid/article/75/11/1971/6570603 .
Although high vaccine effectiveness of mRNA COVID-19 vaccines has been reported in studies in several countries, data are limited from Asian countries, especially against the Delta (B.1.617.2) variant. We conducted a multicenter test-negative case-control study in patients aged ≥16 years visiting hospitals or clinics with signs or symptoms consistent with COVID-19 from 1 July to 30 September 2021, and found mRNA COVID-19 vaccines had high effectiveness against symptomatic SARS-CoV-2 infections in Japan during July–September 2021, when the Delta variant was dominant nationwide.
349.
Amihai Rottenstreich, Olesya Vorontsov, etc.,
Maternal and Neonatal Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Neutralization After Antenatal Messenger RNA Vaccination, 2022.05.24,
https://academic.oup.com/cid/article/75/11/2023/6590984 .
We evaluated the neutralization efficiency against SARS-CoV-2 Omicron variant in maternal and cord blood sera after antenatal BNT162b2 vaccination. Neutralizing antibodies against Omicron were lacking at the time of delivery after 2-dose vaccination. A third booster dose was essential in building neutralizing antibody capacity against Omicron among mothers and neonates.
348.
Char Leung, Li Su, etc.,
Better healthcare can reduce the risk of COVID-19 in-hospital post-partum maternal death: evidence from Brazil, 2022.08.10,
https://academic.oup.com/ije/article/51/6/1733/6659906 .
COVID-19 in post-partum women is commonly overlooked. Post-partum women had almost twice the odds of COVID-19 in-hospital mortality compared with pregnant patients. Part of the mortality risk is preventable through quality healthcare such as the presence of an obstetric centre in the hospital, non-profit private healthcare and hospitals in urban areas.
347.
Kasper P Kepp, Jonas Björk, etc.,
Estimates of excess mortality for the five Nordic countries during the COVID-19 pandemic 2020−2021, 2022.11.04,
https://academic.oup.com/ije/article/51/6/1722/6798817 .
Excess mortality during the COVID-19 pandemic is of major scientific and political interest. Excess mortality during the COVID-19 pandemic is of major scientific and political interest. We show using back-calculation of expected deaths from Nordic all-cause deaths that the Institute for Health Metrics and Evaluation model is a clear outlier in the compared estimates and likely substantially overestimates excess mortality of Finland and Denmark, and probably Sweden.
346.
Neftali Eduardo Antonio-Villa, Omar Yaxmehen Bello-Chavolla, etc.,
Socio-demographic inequalities and excess non-COVID-19 mortality during the COVID-19 pandemic: a data-driven analysis of 1 069 174 death certificates in Mexico, 2022.09.29,
https://academic.oup.com/ije/article/51/6/1711/6731613 .
Socio-demographic inequalities and excess non-COVID-19 mortality during the COVID-19 pandemic: a data-driven analysis of 1 069 174 death certificates in Mexico. Socio-demographic inequalities and excess non-COVID-19 mortality during the COVID-19 pandemic: a data-driven analysis of 1 069 174 death certificates in Mexico. Non-COVID-19 causes of death, largely chronic cardiometabolic conditions, comprised up to one-fifth of excess deaths in Mexico during 2020.
345.
Jessie Zeng, Joshua Szanyi, etc.,
Effectiveness of fourth dose of COVID-19 vaccine against the Omicron variant compared with no vaccination, 2022.12.16,
https://academic.oup.com/ije/advance-article/doi/10.1093/ije/dyac231/6917096?searchresult=1 .
Waning COVID-19 vaccine effectiveness (VE) and the capacity of the Omicron SARS-CoV-2 variant to evade pre-existing immunity have been major impediments to COVID-19 control efforts worldwide. In response, several countries have rolled out fourth-dose COVID-19 vaccination programmes. We find that a fourth dose of the BNT162b2 vaccine appears to restore, if not boost even more, the protection conferred by a third dose at an equivalent time post-vaccination.
344.
Alexandros Mitropoulos, Simon Goodwill, etc.,
The relationship between physical activity and severity of COVID-19 symptoms in non-hospitalized individuals, 2022.07.22,
https://academic.oup.com/eurpub/article/32/5/794/6648347 .
Our findings did not present an association between PA levels and mild-to-moderate COVID-19 symptoms. However, all participants exceeded the lower limit of the World Health Organization recommended, adult PA dose. This might explain the lack of PA effect, on mild-to-moderate symptoms post-COVID-19 infection.
Beijing Interest Group on Global Health and Global Governance
Contact: secretary@bigghgg.cn